Global Ocrevus Market 2026–2035 advancing multiple sclerosis therapies

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Ocrevus Market In 2026 And What Value Is Projected For 2030?

Historically, the expansion observed can be linked to an enhanced comprehension of multiple sclerosis pathology, the authorization of disease-modifying therapies, wider availability of neurology specialty care, escalating MS diagnosis rates, and the presence of biologic infusion infrastructure.

Growth in the forecast period is projected to be driven by the increasing adoption of personalized multiple sclerosis treatment approaches, the expansion of home and outpatient infusion services, rising investments in neuroimmunology research, a growing focus on slowing disease progression, and the development of next-generation monoclonal antibodies. Concurrently, key trends during this period involve the increasing use of monoclonal antibody therapies for MS, rising adoption of B-cell targeted treatments, the expansion of care models centered around infusion centers, a growing emphasis on long-term disease modification, and enhanced patient monitoring paired with real-world evidence collection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20321&type=smp

What Key Drivers Are Influencing The Growth Of The Ocrevus Market?

The increasing incidence of multiple sclerosis (MS) is anticipated to propel the growth of the Ocrevus market moving forward. Multiple sclerosis (MS) is a persistent autoimmune condition that affects the central nervous system, where the body’s immune system mistakenly targets the protective myelin sheath around nerve fibers. The increase in multiple sclerosis (MS) cases is attributed to a combination of genetic, environmental, and lifestyle influences, including enhanced diagnostic techniques, greater public awareness, and changes in diet and urban living. Ocrevus is utilized in the treatment of multiple sclerosis (MS) to diminish disease activity, decelerate progression, and manage symptoms by specifically targeting and reducing CD20-positive B-cells, which contribute to the immune-mediated damage in MS. For instance, in May 2024, according to the MS Society UK, a UK-based non-profit organization, over 150,000 people are living with MS in the UK as of 2024. The prevalence has increased by 15% in England, 10% in Scotland, 9% in Northern Ireland, and 8% in Wales. Therefore, the rising prevalence of multiple sclerosis is expected to drive the Ocrevus market.

What Are The Key Segments Of The Ocrevus Market?

The ocrevus market covered in this report is segmented –

1) By Clinical Indications: Relapsing-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis

2) By Formulation: Liquid Formulations, Tablet Or Capsule Formulation

3) By Route Of Administration: Oral, Injectable

4) By End User: Hospitals, Retail Pharmacies, Online Pharmacies

What Key Trends Are Influencing The Development Of The Ocrevus Market?

Key companies operating within the Ocrevus market are prioritizing the development of innovative solutions, such as subcutaneous combination formulations, to satisfy the growing demand for more convenient administration, improved treatment flexibility, and broader patient access for those with multiple sclerosis. These subcutaneous formulations merge therapeutic monoclonal antibodies with absorption-enhancing agents, facilitating faster delivery and a reduced infusion burden compared to traditional intravenous dosing, which necessitates extended administration times in clinical settings. For example, in September 2024, Genentech Inc., a US-based biotechnology company, announced that the United States Food and Drug Administration (U.S. FDA) had approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for treating both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo represents the first and only subcutaneous (SC) injection that healthcare professionals can administer twice yearly, taking approximately 10 minutes per session. This pivotal approval provides individuals living with multiple sclerosis (MS) with enhanced treatment options and greater adaptability for healthcare providers to tailor care to the unique needs of each patient.

Who Are The Leading Companies Operating In The Ocrevus Market?

Major companies operating in the ocrevus market are F. Hoffmann-La Roche Ltd.

Read the full ocrevus market report here:

https://www.thebusinessresearchcompany.com/report/ocrevus-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Ocrevus Market?

North America was the largest region in the ocrevus market in 2025. The regions covered in the ocrevus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Ocrevus Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20321&type=smp

Browse Through More Reports Similar to the Global Ocrevus Market 2026, By The Business Research Company

White Inorganic Pigments Market Report 2026

https://www.thebusinessresearchcompany.com/report/white-inorganic-pigments-global-market-report

Oral Antidiabetic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report

Odbc Market Report 2026

https://www.thebusinessresearchcompany.com/report/odbc-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795